3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
6
Polycystic Ovary Syndrome
2
Obesity
2
Diabetes Mellitus
2
Stroke
1
Sedentary Behavior
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Kidney Diseases
1
Insulin Resistance
1
Hypertension
1
Heart Failure
1
Frailty
1
Endometrial Neoplasms
1
Diabetes Mellitus, Type 2
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Body Weight
1
Arthritis
1
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
Resistance Training
×
Clear all
No trials found.